Compare Airbnb, Inc. (ABNB) vs Abbott Laboratories (ABT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Airbnb, Inc. vs Abbott Laboratories — how do they compare? Airbnb, Inc. trades at $180.68 (market cap $110.76B), while Abbott Laboratories trades at $109.58 (market cap $187.95B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.32% dividend while Airbnb, Inc. pays none. Which is the better fit depends on your goals.
| ABNB | ABT | |
|---|---|---|
Market Cap | $110.76B | $187.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $136.62 |
52-Week Low | $111.54 | $82.57 |
Enterprise Value | $101.19B | $214.96B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABNB trades at $184.70, up 3.72% in 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving averages and recent earnings beat in Q2 2026. Revenue growth is steady, with 2025 revenue at $12.24 billion and net income of $2.51 billion, though Q4 2025 and Q1 2026 EPS missed expectations. Analyst sentiment is mixed with a consensus price target of $173.26, below the current price, and news highlights AI-driven growth initiatives.
Outlook is cautiously optimistic with AI expansion boosting bookings and margins, but high valuation ratios like a P/E of 42.23 pose risks. Competition and economic sensitivity are key concerns. Institutional holdings and bullish technical trends support upside potential if execution continues.
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →
